MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$148M+190.7% YoY

Gross Profit

$117M78.8% margin

Operating Income

$91M61.5% margin

Net Income

$23M15.6% margin

EPS (Diluted)

$0.24

QoQ Revenue Growth

+50.7%

Cash Flow

Operating Cash Flow

$38M

Free Cash Flow

$35M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$1.1B

Stockholders' Equity

$113M

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$148M	$51M	+190.7%
Gross Profit	$117M	$36M	+227.4%
Operating Income	$91M	$35M	+161.9%
Net Income	$23M	$23M	-1.2%

Revenue Segments

Nucleic Acid Production Segment

$372M84%

Biologics Safety Testing Segment

$53M12%

Protein Detection Segment

$20M4%

Geographic Segments

North America

$78M53%

EMEA

$54M36%

Asia Pacific

$16M11%

Latin And Central America

$220,0000%

MRVI Q1 2021 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena